CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 2012-- Selventa(TM), a biomarker discovery company that enables personalized healthcare, today announced that William Hayes, Ph.D. has been appointed Senior Vice President of Platform Development effective immediately. Dr.
Hayes brings over 15 years of managing and supporting Informatics and IT solutions to the cross-functional internal team members at various pharmaceutical and biotechnology organizations. His new role includes managing and developing the discovery platform supporting Selventa's scientists and customers.
"William is an innovative, thoughtful and visionary data scientist," said David de Graaf, President and CEO of Selventa. "His extensive experience with bioPharma Informatics as well as data management platform development and delivery will be invaluable in enhancing the capabilities of the Selventa Discovery Platform for biomarker discovery. We are extremely pleased to have William help us drive the vision of enabling personalized healthcare through implementation of a sophisticated, user-friendly, customizable platform for our scientists." Selventa utilizes molecular patient data and Selventa Discovery Platform to derive mechanistic understanding of disease biology and unambiguously identify patient subsets based on their disease-driving mechanisms to enable personalized healthcare. This includes assessment of single and combination therapies, segmentation of potential responder and non-responder populations, evaluation of alternative indications, and optimization of proof-of-concept clinical trial design through stratification biomarker panels.
"My vision is to make the Selventa Discovery Platform an extremely powerful analytical tool for our internal as well as external research efforts," said Dr. Hayes. "In order to achieve this vision, the immediate goal is to extend the Selventa Discovery Platform to efficiently analyze new experimental assay data types and significantly increase the depth and breadth of our capabilities for more sophisticated analyses. I anticipate that this will result in decreasing timelines for biomarker discovery and increasing research productivity." Before joining Selventa, Dr. Hayes was the Director of Decision Support and Literature Informatics, R&D IT at Biogen Idec. In this role, he was responsible for providing decision support capabilities for R&D scientists. Notably, he evolved a Corporate Library into a Literature Informatics team using state of the art text analytics and visualizations to support Biogen Idec from Discovery to the Board Room and deployed an agile data management platform based on Semantic Web.
Prior to Biogen Idec, William worked at AstraZeneca and GSK in the Bioinformatics Departments. He received his BS in Aerospace Engineering and Ph.D. in Applied Biology and Bioinformatics from Georgia Institute of Technology in Atlanta, GA.
About Selventa Founded in 2002 and privately-held, Selventa collaborates with partners to match the optimal treatments for the right patients. The company analyzes molecular patient data to identify key disease-driving mechanisms and accelerates the development process to clarify therapeutic and diagnostic decisions through identification and development of biomarkers for patient stratification. Selventa engages in strategic relationships with leading pharmaceutical and life science companies including clinical research organizations, diagnostic companies and reference laboratories to enable personalized healthcare primarily in autoimmune diseases and oncology. For more information, visit www.selventa.com.
CONTACT: Selventa Diane H. Song, Ph.D., 617-547-5421 x235 firstname.lastname@example.org or For Selventa Paul Kidwell, 617-296-3854 email@example.com KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL GENERAL HEALTH SOURCE: Selventa Copyright Business Wire 2012 PUB: 04/17/2012 08:00 AM/DISC: 04/17/2012 08:00 AM http://www.businesswire.com/news/home/20120417005084/